(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 May 2023 (04.05.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/073084 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 31/04* (2006.01)
A61K 39/395 (2006.01) *A61P 31/14* (2006.01)

(21) International Application Number:
PCT/EP2022/080048

(22) International Filing Date:
27 October 2022 (27.10.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
21306505.5 27 October 2021 (27.10.2021) EP

(71) Applicants: **IMCHECK THERAPEUTICS** [FR/FR]; 180 avenue du Prado, 13008 MARSEILLE (FR). **INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)** [FR/FR]; 101, rue de Tolbiac, 75013 PARIS (FR). **UNIVERSITÉ D'AIX-MARSEILLE** [FR/FR]; 58 Boulevard Charles Livon, 13007 MARSEILLE (FR). **CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE** [FR/FR]; 3, rue Michel Ange, 75016 PARIS (FR). **INSTITUT JEAN PAOLI & IRENE CALMETTES** [FR/FR]; 232 boulevard Sainte-Marguerite, 13009 MARSEILLE (FR). **ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE** [FR/FR]; 80 rue Brochier, 13005 MARSEILLE (FR). **INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT (IRD)** [FR/FR]; Immeuble le Sextant 44 Bd Dunkerque CS90009, 13002 MARSEILLE 2 (FR).

(72) Inventors: **OLIVE, Daniel**; 56 avenue Massenet, 13009 MARSEILLE (FR). **MEZOUAR, Soraya**; 29 rue de Lissandre, La Batarelle Haute, 13014 MARSEILLE (FR). **MEGE, Jean-Louis**; 6 rue François Blanc, 13009 MARSEILLE (FR). **FROHNA, Paul**; C/O Imcheck Therapeutics SAS, 31 chemin Joseph Aiguier CS70071, 13402 MARSEILLE CEDEX 09 (FR). **TRUNEH, Alemseged**; 93 Atkinson Lane, SUDBURY, MA 01776 (US). **GAY, Laetitia**; C/O IMCHECK THERAPEUTICS SAS 31 chemin Joseph Aiguier - CS70071, 13402 MARSEILLE CEDEX 09 (FR).

(74) Agent: **PLASSERAUD IP**; 66 rue de la Chaussée d'Antin, 75440 PARIS CEDEX 09 (FR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2023/073084 A1

(54) Title: BUTYROPHILIN (BTN) 3A ACTIVATING ANTIBODIES FOR USE IN METHODS FOR TREATING INFECTIOUS DISORDERS

(57) Abstract: The present disclosure relates to methods for treating infectious disorders. In particular, the disclosure provides BTN3A activating antibodies, and their use in treating infectious disorders in a human subject in need thereof, such as disorders caused by SARS-Cov2 or Coxiella burnetii infection.